Skip to main content
Livermore
Livermore
ZHEN

RVL Pharmaceuticals plc

RVLPDelisted Nov 20, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001739426

RVL Pharmaceuticals plc was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Oct 23, 2023; 32 institutions reported holding it in 13F filings for Q3 2023, worth $1.57M in total; no superinvestor held it.

Q1 2023 vs. Q4 2022

How the institutions holding RVL Pharmaceuticals plc changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of RVLP: Q4 2022 compared with Q1 2023
MeasureQ4 2022Of which not filed for Q1 2023Q1 2023Change
Holders36141+6
Shares25.1M92.5K25.2M+149.7K (+0.6%)
Value$28.0M$103.6K$28.7M+$789.8K (+2.8%)

1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held RVL Pharmaceuticals plc at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to RVLP in Q1 2023
InstitutionSharesValue% of portfolio
Scoggin Management LP500,000$570.0K0.83%
UBS Oconnor LLC276,428$315.1K0.01%
Titleist Asset Management, LLC105,003$119.7K0.03%
LPL Financial LLC21,210$24.2K0.00%
Jane Street Group, LLC17,785$20.3K0.00%
Squarepoint Ops LLC11,299$12.9K0.00%
Dakota Community Bank & Trust NA3,980$4.54K0.03%
Tower Research Capital LLC (TRC)2,645$3.00K0.00%

Sold out (2)

Institutions that held RVL Pharmaceuticals plc at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of RVLP in Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
Virtu Financial LLC39,818$45.0K
Two Sigma Advisers, LP14,100$15.8K

Not filed for Q1 2023 yet (1)

Institutions that held RVL Pharmaceuticals plc at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding RVLP in Q4 2022 that haven't filed for Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
Titleist Asset Management, Ltd.92,503$103.6K